Related Experiment Video
Updated: Jun 17, 2025
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Alvan Cai1, Yuan Chen2, Lily S Wang3
1College of Medicine, California Northstate University, Elk Grove, CA 95757, USA.
Abstract:
HER2 (human epidermal growth factor receptor 2) is highly expressed in a variety of cancers, including breast, lung, gastric, and pancreatic cancers. Its amplification is linked to poor clinical outcomes. At the genetic level, HER2 is encoded by the ERBB2 gene (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), which is frequently mutated or amplified in cancers, thus spurring extensive research into HER2 modulation and inhibition as viable anti-cancer strategies. An impressive body of FDA-approved drugs, including anti-HER2 monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and HER2-tyrosine kinase inhibitors (TKIs), have demonstrated success in enhancing overall survival (OS) and disease progression-free survival (PFS). Yet, drug resistance remains a persistent challenge and raises the risks of metastatic potential and tumor relapse. Research into alternative therapeutic options for HER2+ breast cancer therefore proves critical for adapting to this ever-evolving landscape. This review highlights current HER2-targeted therapies, discusses predictive biomarkers for drug resistance, and introduces promising emergent therapies-especially combination therapies-that are aimed at overcoming drug resistance in the context of HER2+ breast cancer.
Insights
HER2-targeted therapies show promise for various cancers, but drug resistance is a major hurdle. New combination strategies are being explored to overcome resistance in HER2-positive breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2 (human epidermal growth factor receptor 2) is overexpressed in multiple cancers, correlating with poor prognosis.
- ERBB2 gene amplification drives HER2 overexpression, making it a key therapeutic target.
- Current FDA-approved therapies include monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors.
Purpose of the Study:
- To review current HER2-targeted therapies for HER2-positive breast cancer.
- To discuss biomarkers predicting resistance to HER2-targeted treatments.
- To introduce novel combination therapies designed to overcome drug resistance.
Main Methods:
- Literature review of current and emerging HER2-targeted therapies.
- Analysis of predictive biomarkers for drug resistance.
- Exploration of combination therapy strategies.
Main Results:
- Established HER2-targeted therapies improve survival but face challenges with drug resistance.
- Biomarkers are crucial for predicting treatment response and resistance.
- Emerging combination therapies show potential in overcoming resistance mechanisms.
Conclusions:
- Overcoming drug resistance is critical for improving outcomes in HER2-positive breast cancer.
- Combination therapies represent a promising avenue for enhancing treatment efficacy.
- Continued research into novel therapeutic strategies is essential for managing HER2-driven cancers.
More Related Videos
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle